

# Traitement des éventrations et hernies ombilicales avec Symbotex™ Composite Mesh: Résultats à 1 an d'un registre prospectif



Presented by:  
Dr. Constantin Zaranis, MD<sup>1</sup>


<sup>1</sup>Clinique du Mail, La Rochelle, France

# Disclosures – Constantin Zaranis

SymCHro study sponsorship, funding, and data analysis was provided by:

**Medtronic**

# Symbotex™ Composite Mesh



- Mesh transparency for increased visibility during placement<sup>1</sup>
- Green orientation marking for accurate positioning<sup>1,2</sup>
- Abdominal wall side: monofilament 3D polyester textile
- Visceral side: hydrophilic collagen bioabsorbable film
- Large pore size: 3.3 mm × 2.3 mm

# Mesh Porosity Matters


International Journal of Surgery 22 (2015) 46–53

Contents lists available at [ScienceDirect](#)

 **ELSEVIER**

International Journal of Surgery

journal homepage: [www.journal-surgery.net](http://www.journal-surgery.net)



Original research

Large pore size and controlled mesh elongation are relevant predictors for mesh integration quality and low shrinkage – Systematic analysis of key parameters of meshes in a novel minipig hernia model<sup>☆</sup>

Dirk Weyhe <sup>a,\*</sup>, William Cobb <sup>b</sup>, Julie Lecuivre <sup>c</sup>, Antoine Alves <sup>d</sup>, Sebastien Ladet <sup>c</sup>, Davide Lomanto <sup>e</sup>, Yves Bayon <sup>c</sup>

 CrossMark

Methodology: Preclinical study of PET mesh integration and shrinkage comparing mesh weight (HW vs LW), pore size (SP vs LP) and weave (2D vs 3D)

- Large pore mesh showed better integration than small pore mesh
- Lightweight small pore mesh exhibited the most shrinkage
- 3D mesh supported the highest collagen count and exhibited the least shrinkage

➔ **Mesh porosity is more important than mesh density for tissue integration**

# Study Design

Observational registry study: the short and long-term clinical outcomes following the use of Symbotex™ composite mesh.

- 100 consecutive patients reported in the Hernia Club database
- 2 Years Follow-up
- Inclusion Criteria:
  - ✓  $\geq 18$  years of age
  - ✓ Ventral hernia: Primary or incisional
- Exclusion Criteria:
  - ✓ None
- ✓ Surgical technique is left to the surgeon's preference



# Study Endpoints

## Primary Endpoints:


- Peri-operative complications
- Post-operative complications (up to 2 year follow-up)

## Secondary Endpoints:

- Operative time and hospital stay
- Quality of life and patient satisfaction
- Ease of use / mesh manipulability assessment by surgeons

# Patient Follow-Up (as of July 2016)

## Study Flow Chart




**Median Follow-Up:**  
**349.5 (0 – 579) days**

**On-going study will assess 24 months follow- up**



# Patient Demographics & Risk Factors



| <b>Median Age (min – max)</b> |    |
|-------------------------------|----|
| 61.5 years (30-91)            |    |
| <b>Gender (N= 100)</b>        |    |
| Male                          | 49 |
| Female                        | 51 |


  

| <b><u>Daily / Regular Smoker</u></b>                                  | Count |
|---|-------|
| <b><u>Risk factors related to healing (<math>\geq</math>1)</u></b>    | 32    |
| Anticoagulant treatment or bleeding disorder                          | 18    |
| Chemotherapy/immunosuppressive treatment                              | 8     |
| Diabetes  | 7     |
| <b><u>Risk factors related to dissection (<math>\geq</math>1)</u></b> | 68    |
| Prior intraperitoneal surgery   | 55    |
| Mac Burney  | 16    |
| Prior extraperitoneal surgery   | 7     |


0% 10% 20% 30% 40% 50% 60% 70% 80%  
Patients (%)

# Hernia Characteristics


Hernia Type (N=105)




Multi-site hernias (N=104)



Hernia Defect Area (N=104)






Hernia Symptoms (N=103)




# Operative Data

## Surgical Approach



# Surgeon Satisfaction



# Patient Complications

- One recurrence occurred, patient was reoperated on
- Few complications occurred
- No sepsis or other serious adverse events were reported within 12 months

## Patient Complications

| Complication                  | Symbotex™ composite mesh (N=100) | Time of occurrence           |
|-------------------------------|----------------------------------|------------------------------|
| Seroma <sup>1</sup>           | 1                                | Perioperative                |
|                               | 5                                | Post-operative (2-4 weeks)   |
|                               | <b>6 (6.0%)</b>                  | <b>Total within one year</b> |
| Transitory ileus <sup>2</sup> | 2                                | Perioperative                |
|                               | 1                                | Post-operative (2-4 weeks)   |
|                               | <b>3 (3.0%)</b>                  | <b>Total within one year</b> |
| Recurrence <sup>3</sup>       | <b>1 (1.0%)</b>                  | <b>Total within one year</b> |

Data are represented as n (%)


<sup>1</sup> No seroma were mesh-related; five were minor, requiring no medical treatment; one diagnosed at 1 month was punctured at 2 months post-surgery

<sup>2</sup> All were low-grade (Clavien 1 or 2); relation to mesh or procedure is unknown at this time

<sup>3</sup> Asymptomatic occurring between 6 – 12 months, patient was reoperated on.

# Post-Operative Pain

## VAS Pain Assessment



\*  $P < 0.0001$  for scores relative to baseline, based on Wilcoxon signed rank test (non-parametric) for paired data.


At 12 months, patients were given a questionnaire without VAS pain assessment

# Patient Satisfaction

## Patient Satisfaction Survey by Phone at One Year

| <b>Patient satisfaction rating</b> | <b>Responses (N=94)</b> |
|------------------------------------|-------------------------|
| <b>Excellent</b>                   | <b>10 (10.6%)</b>       |
| <b>Good</b>                        | <b>73 (77.7%)</b>       |
| <b>Medium</b>                      | <b>7 (7.4%)</b>         |
| <b>Bad</b>                         | <b>4 (4.3%)</b>         |

# Conclusions

- 
- **Primary and incisional ventral hernia repair with Symbotex™ composite mesh yielded minimal adverse events with only one recurrence**
  - **High patient satisfaction at one year follow-up and high rate of surgeon satisfaction regarding mesh handling reported**
  - **Post-operative pain decreased significantly**
  - **These promising results support the use of Symbotex™ composite mesh in primary and incisional ventral hernia repair**

**Study results will be assessed again at two year follow-up**